CHMP Backs Encorafenib Plus Cetuximab and FOLFOX as First-Line Option for BRAF V600E–Mutant mCRC – OncLive
- CHMP Backs Encorafenib Plus Cetuximab and FOLFOX as First-Line Option for BRAF V600E–Mutant mCRC OncLive
- Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic color The Manila Times
0
Views